These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
151 related items for PubMed ID: 6148880
1. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. Gatta A, Sacerdoti D, Merkel C, Milani L, Battaglia G, Zuin R. Am Heart J; 1984 Oct; 108(4 Pt 2):1167-72. PubMed ID: 6148880 [Abstract] [Full Text] [Related]
2. Use of a nonselective beta-blocker, nadolol, in the treatment of portal hypertension in cirrhotics. Gatta A, Sacerdoti D, Merkel C, Rossoni R, Finucci G, Bolognesi M, Zuin R. Int J Clin Pharmacol Res; 1985 Oct; 5(6):413-8. PubMed ID: 4093219 [Abstract] [Full Text] [Related]
3. Long-term effects of beta-adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics. Gatta A, Bolognesi M, Merkel C, Finucci GF, Angeli P, Sacerdoti D, Ruol A. Clin Physiol; 1987 Oct; 7(5):377-87. PubMed ID: 3665396 [Abstract] [Full Text] [Related]
7. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, Kidokoro H, Harimoto H, Fukuda T, Matsushita Y, Nakatsuka K, Sakamoto C. J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420 [Abstract] [Full Text] [Related]
10. Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Cavasin L, Gatta A. Aliment Pharmacol Ther; 2005 Sep 01; 22(5):433-9. PubMed ID: 16128681 [Abstract] [Full Text] [Related]
11. Preventing the development of varices in cirrhosis. Garcia-Tsao G. J Clin Gastroenterol; 2007 Sep 01; 41 Suppl 3():S300-4. PubMed ID: 17975480 [Abstract] [Full Text] [Related]
12. Hemodynamic assessment of pharmacological response in the treatment of portal hypertension: a need to know. Grace ND. Am J Gastroenterol; 2000 Aug 01; 95(8):1862-4. PubMed ID: 10950027 [No Abstract] [Full Text] [Related]
13. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients. O'Callaghan WG, Laher MS, McGarry K, O'Brien E, O'Malley K. Br J Clin Pharmacol; 1983 Oct 01; 16(4):417-21. PubMed ID: 6138058 [Abstract] [Full Text] [Related]
17. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, Bosch J. Hepatology; 1999 Jul 01; 30(1):79-83. PubMed ID: 10385642 [Abstract] [Full Text] [Related]
18. [Use of esmolol in patient with portal hypertension]. Figueroa Yusta J, Gilsanz F, De Dios Tomás E. Rev Esp Anestesiol Reanim; 2001 Jul 01; 48(7):349. PubMed ID: 11591288 [No Abstract] [Full Text] [Related]
20. [Effects of acute octreotide infusion on renal function in patients with cirrhosis and portal hypertension]. Silva G, Segovia R, Backhouse C, Palma M, Márquez S, Iturriaga H. Rev Med Chil; 2004 Feb 01; 132(2):144-50. PubMed ID: 15449549 [Abstract] [Full Text] [Related] Page: [Next] [New Search]